Chromogranin peptides in Alzheimer's disease

Synaptic disturbances may play a key role in the pathophysiology of Alzheimer's disease. To characterize differential synaptic alterations in the brains of Alzheimer patients, chromogranin A, chromogranin B and secretoneurin were applied as soluble constituents for large dense core vesicles, synaptophysin as a vesicle membrane marker and calbindin as a cytosolic protein. In controls, chromogranin B and secretogranin are largely co-contained in interneurons, whereas chromogranin A is mostly found in pyramidal neurons. In Alzheimer's disease, about 30% of beta-amyloid plaques co-labelled with chromogranin A, 20% with secretoneurin and 15% with chromogranin B. Less than 5% of beta-amyloid plaques contained synaptophysin or calbindin, respectively. Semiquantitative immunohistochemistry revealed a significant loss for chromogranin B- and secretoneurin-like immunoreactivity in the dorsolateral, the entorhinal, and orbitofrontal cortex. Chromogranin A displayed more complex changes. It was the only chromogranin peptide to be expressed in glial fibrillary acidic protein containing cells. About 40% of chromogranin A immunopositive plaques and extracellular deposits were surrounded and pervaded by activated microglia. The present study demonstrates a loss of presynaptic proteins involved in distinct steps of exocytosis. An imbalanced availability of chromogranins may be responsible for impaired neurotransmission and a reduced functioning of dense core vesicles. Chromogranin A is likely to be a mediator between neuronal, glial and inflammatory mechanisms found in Alzheimer disease.

[1]  P. Ruck,et al.  Immunoreactivity of neoplastic and non-neoplastic hepatocytes for CD68 and with 3A5, Ki-M1P, and MAC387 light- and electron-microscopic findings , 1995 .

[2]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[3]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE) Signaling Induces CREB-dependent Chromogranin Expression during Neuronal Differentiation* , 2002, The Journal of Biological Chemistry.

[4]  J. Marksteiner,et al.  Distribution of Secretoneurin‐like Immunoreactivity in Comparison with Substance P‐ and Enkephalin‐like Immunoreactivities in Various Human Forebrain Regions , 1993, The European journal of neuroscience.

[5]  P. Baron,et al.  Glial activation in Alzheimer’s disease: the role of Aβ and its associated proteins , 2001, Neurobiology of Aging.

[6]  E B Mukaetova-Ladinska,et al.  Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. , 2000, The American journal of pathology.

[7]  D. Munoz,et al.  Chromogranin A-like immunoreactivity in the human brain: Distribution in bulbar medulla and cerebral cortex , 1990, Neuroscience.

[8]  Y. Loh,et al.  The role of chromogranin A and the control of secretory granule genesis and maturation , 2003, Trends in Endocrinology & Metabolism.

[9]  Moon Kyung Kang,et al.  Localization of the Secretory Granule Marker Protein Chromogranin B in the Nucleus , 2002, The Journal of Biological Chemistry.

[10]  P. Hanson,et al.  Synaptobrevin binding to synaptophysin: a potential mechanism for controlling the exocytotic fusion machine. , 1995, The EMBO journal.

[11]  T. Kosaka,et al.  GABAergic neurons containing CCK‐8‐like and/or VIP‐like immunoreactivities in the rat hippocampus and dentate gyrus , 1985, The Journal of comparative neurology.

[12]  Brian J Cummings,et al.  β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.

[13]  P. Emson,et al.  Relationship of calbindin D28K‐immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease , 2001, Neuropathology : official journal of the Japanese Society of Neuropathology.

[14]  D. Mann,et al.  Pathological relationships between microglial cell activity and tau and amyloid β protein in patients with Alzheimer's disease , 2002, Neuroscience Letters.

[15]  J. Morris The Clinical Dementia Rating (CDR) , 1993, Neurology.

[16]  W. Huttner,et al.  Essential Role of the Disulfide-bonded Loop of Chromogranin B for Sorting to Secretory Granules Is Revealed by Expression of a Deletion Mutant in the Absence of Endogenous Granin Synthesis , 1998, The Journal of cell biology.

[17]  S. Hsu,et al.  Protein A, avidin, and biotin in immunohistochemistry. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[18]  Bertram Wiedenmann,et al.  Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles , 1985, Cell.

[19]  W. Huttner,et al.  The disulfide‐bonded loop of chromogranin B mediates membrane binding and directs sorting from the trans‐Golgi network to secretory granules , 1999, The EMBO journal.

[20]  R. Veerhuis,et al.  Neuroinflammation in Alzheimer's disease and prion disease , 2002, Glia.

[21]  H. Wacker,et al.  Detection of a monocyte/macrophage differentiation antigen in routinely processed paraffin-embedded tissues by monoclonal antibody Ki-M1P. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[22]  James P. O'Callaghan,et al.  Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse , 2002, Experimental Neurology.

[23]  H. Hinterhuber,et al.  Synaptic loss reflected by secretoneurin‐like immunoreactivity in the human hippocampus in Alzheimer's disease , 1998, The European journal of neuroscience.

[24]  Y. Loh,et al.  Chromogranin A, an “On/Off” Switch Controlling Dense-Core Secretory Granule Biogenesis , 2001, Cell.

[25]  W. Snow,et al.  The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease , 1988, Neurology.

[26]  C. Rabiner,et al.  Characterization of neuronal dystrophy induced by fibrillar amyloid β: implications for Alzheimer’s disease , 2002, Neuroscience.

[27]  G. McCormack,et al.  Neurochemical Diversity of Dystrophic Neurites in the Early and Late Stages of Alzheimer's Disease , 1999, Experimental Neurology.

[28]  K. Jellinger,et al.  Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia , 2002, Schizophrenia Research.

[29]  R. Fischer‐Colbrie,et al.  The chromogranins A and B: The first 25 years and future perspectives , 1992, Neuroscience.

[30]  M. Cuzner,et al.  Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up‐regulated in Alzheimer's disease , 2002, Journal of neurochemistry.

[31]  F. Wouterlood,et al.  Double-label immunocytochemistry: combination of anterograde neuroanatomical tracing with Phaseolus vulgaris leucoagglutinin and enzyme immunocytochemistry of target neurons. , 1987, Journal of Histochemistry and Cytochemistry.

[32]  W. Honer,et al.  Correlations of synaptic and pathological markers with cognition of the elderly , 1995, Neurobiology of Aging.

[33]  L. Lue,et al.  Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. , 1996, Journal of neuropathology and experimental neurology.

[34]  S. Mahata,et al.  Desensitization of Catecholamine Release , 1999, The Journal of Biological Chemistry.

[35]  J. Marksteiner,et al.  PE-11, a peptide derived from chromogranin B, in the human brain , 1999, Neuroscience.

[36]  P. Greengard,et al.  Protein p38: an integral membrane protein specific for small vesicles of neurons and neuroendocrine cells , 1986, The Journal of cell biology.

[37]  W. Prodinger,et al.  Differential chemotactic activities of sensory neuropeptides for human peripheral blood mononuclear cells. , 1997, Journal of immunology.

[38]  W. Paulus,et al.  Ki-M1P as a marker for microglia and brain macrophages in routinely processed human tissues , 2004, Acta Neuropathologica.

[39]  S. Mirra The CERAD Neuropathology Protocol and Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease: A Commentary , 1997, Neurobiology of Aging.

[40]  E. Masliah,et al.  E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer’s disease , 2000, Neurology.

[41]  K. Jellinger,et al.  Neuropathology of Alzheimer's disease: a critical update. , 1998, Journal of neural transmission. Supplementum.

[42]  K. Jellinger,et al.  Synaptic pathology in alzheimer's disease: Immunological data for markers of synaptic and large dense-core vesicles , 1992, Neuroscience.

[43]  I. Ferrer,et al.  Dystrophic Neurites of Senile Plaques are Defective in Proteins Involved in Exocytosis and Neurotransmission , 1998, Journal of neuropathology and experimental neurology.

[44]  D. Aunis,et al.  Chromogranin a triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells , 1996, Neuroscience.

[45]  P. Greengard,et al.  Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. , 2002, The American journal of pathology.

[46]  J. Marksteiner,et al.  Rat Brain: Distribution of Immunoreactivity of PE‐11, a Peptide Derived from Chromogranin B , 1996, The European journal of neuroscience.

[47]  D. Munoz Chromogranin A-like immunoreactive neurites are major constituents of senile plaques. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[48]  A. Gundlach,et al.  Chromogranin mRNA Levels in the Brain as a Marker for Acute and Chronic Changes in Neuronal Activity: Effect of Treatments Including Seizures, Osmotic Stimulation and Axotomy in the Rat , 1996, The European journal of neuroscience.

[49]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[50]  C. M. Huang,et al.  Proteomic analysis of proteins in PC12 cells before and after treatment with nerve growth factor: increased levels of a 43-kDa chromogranin B-derived fragment during neuronal differentiation. , 2001, Brain research. Molecular brain research.

[51]  J. Pocock,et al.  Microglial secreted cathepsin B induces neuronal apoptosis , 2001, Journal of neurochemistry.

[52]  P. Mcgeer,et al.  Two types of dystrophic neurites in senile plaques of alzheimer disease and elderly non-demented cases , 1994, Neuroscience Letters.

[53]  D. Alkon,et al.  TNF‐α induced over‐expression of GFAP is associated with MAPKs , 2000, Neuroreport.

[54]  W. Huttner,et al.  The granin (chromogranin/secretogranin) family. , 1991, Trends in biochemical sciences.

[55]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[56]  R. Kirchmair,et al.  Secretoneurin—a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C) , 1993, Neuroscience.

[57]  K. Jellinger,et al.  Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer’s disease , 2000, Acta Neuropathologica.

[58]  W. Honer,et al.  Topographical distribution of synaptic-associated proteins in the neuritic plaques of Alzheimer's disease hippocampus , 2004, Acta Neuropathologica.

[59]  P. Mcgeer,et al.  Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases , 1994, Neuroscience Letters.